PT  - JOURNAL ARTICLE
AU  - Lista, Maria Jose
AU  - Page, Robert
AU  - Sertkaya, Helin
AU  - Matos, Pedro M.
AU  - Ortiz-Zapater, Elena
AU  - Maguire, Thomas J. A.
AU  - Poulton, Kate
AU  - O’Byrne, Aoife M.
AU  - Bouton, Clement
AU  - Dickenson, Ruth E
AU  - Ficarelli, Mattia
AU  - Howard, Mark
AU  - Betancor, Gilberto
AU  - Galao, Rui Pedro
AU  - Pickering, Suzanne
AU  - Signell, Adrian W
AU  - Wilson, Harry
AU  - Cliff, Penny
AU  - Kia Ik, Mark Tan
AU  - Patel, Amita
AU  - MacMahon, Eithne
AU  - Cunningham, Emma
AU  - Agromayor, Monica
AU  - Martin-Serrano, Juan
AU  - Perucha, Esperanza
AU  - Mischo, Hannah E.
AU  - Shankar-Hari, Manu
AU  - Batra, Rahul
AU  - Edgeworth, Jonathan
AU  - Malim, Michael H.
AU  - Neil, Stuart
AU  - Martinez-Nunez, Rocio Teresa
TI  - Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation
AID  - 10.1101/2020.04.22.20074351
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.22.20074351
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.22.20074351.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.22.20074351.full
AB  - There is a worldwide shortage of reagents to perform detection of SARS-CoV-2. Many clinical diagnostic laboratories rely on commercial platforms that provide integrated end-to-end solutions. While this provides established robust pipelines, there is a clear bottleneck in the supply of reagents given the current situation of extraordinary high demand. Some laboratories resort to implementing kit-free handling procedures, but many other small laboratories will not have the capacity to develop those and/or will perform manual handling of their samples. In order to provide multiple workflows for SARS-CoV-2 nucleic acid detection we compared several commercially available RNA extraction methods: QIAamp Viral RNA Mini Kit (QIAGEN), the recently developed RNAdvance Blood (Beckman) and Mag-Bind Viral DNA/RNA 96 Kit (Omega Bio-tek). We also compared different 1-step RT-qPCR Master Mix brands: TaqMan™ Fast Virus 1-Step Master Mix (ThermoFisher Scientific), qPCRBIO Probe 1-Step Go Lo-ROX (PCR Biosystems) and Luna® Universal Probe One-Step RT-qPCR Kit (NEB). We used the Centre for Disease Control (CDC) recommended primers that detect two regions of the viral N gene as well as those that detect the RdRP gene region as per Public Health England (PHE) guidelines (Charité/WHO/PHE). Our data show that the RNA extraction methods provide similar results. Amongst the qPCR reagents tested, TaqMan™ Fast Virus 1-Step Master Mix and Luna® Universal Probe One-Step RT-qPCR Kit proved most sensitive. The N1 and N2 primer-probes provide a more reliable detection than the RdRP_SARSr primer-probe set, particularly in samples with low viral titres. Importantly, we have implemented a protocol using heat inactivation and demonstrate that it has minimal impact on the sensitivity of the qPCR in clinical samples – potentially making SARS-CoV-2 testing portable to settings that do not have CL-3 facilities.In summary, we provide several testing pipelines that can be easily implemented in other laboratories and have made all our protocols and SOPs freely available at https://osf.io/uebvj/.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/uebvj/ Funding StatementThis work was funded by King's Together Rapid COVID-19 Call award to R.T.M-N. A.S. was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); EOZ was supported by MR/S009191/1 to Parsons M and Santis G; M.F. was supported by the UK Medical Research Council (MR/R50225X/1) and is a King’s College London member of the MRC Doctoral Training Partnership in Biomedical Sciences; R.E.D. is a King’s College London member of the MRC Doctoral Training Partnership in Biomedical Sciences; H.S was supported by the BBSRC (BB/P504609/1); G.B. was supported by the Wellcome Trust (106223/Z/14/Z to MHM); R.P. was supported by the by the (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London; T.J.A.M. was supported by Asthma UK at the Asthma UK Centre in Allergic Mechanisms of Asthma; P.M., S. P. and H.W. were supported by WT098049AIA to Neil S. and Swanson C.; M.J.L.B and C.B. were supported by MRC: MR/S000844/1 to Neil S. and Swanson C. This UK funded award is part of the EDCTP2 programme supported by the European Union; K.P. was funded by KHP Challenge Fund to R.T.M-N; M.H. was funded by RP_007_20190305 from Kidney research UK; H.M. was funded by the Wellcome Trust and Royal Society Sir Henry Dale Fellowship 218537/Z/19/Z.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data files are available to anyone that requires them. Our protocols are also published at https://osf.io/uebvj/